Critical-Illness-Related Hypercortisolism: Clinical Insights, Mechanisms, and Management

Abstract

Critical-illness-related hypercortisolism (CIR-H) is a complex endocrine response observed in patients with severe systemic illness. This review explores the epidemiology, pathophysiology, risk factors, clinical manifestations, diagnostic challenges, and management strategies of CIR-H, synthesizing recent evidence and guideline-based recommendations. The discussion highlights both the adaptive and maladaptive aspects of CIR-H, clinical implications for intensive care, and emerging therapeutic approaches. Practical insights for healthcare professionals are provided to facilitate timely recognition and optimal management of this underappreciated phenomenon.

Introduction

Critical illness precipitates profound physiological and metabolic stress, triggering adaptive endocrine responses to maintain homeostasis and enhance survival. Among these, hypercortisolism is a hallmark of the acute phase of critical illness, characterized by elevated circulating cortisol levels. While initially protective, persistent or excessive hypercortisolism may contribute to adverse outcomes through immune modulation, catabolism, and metabolic disturbances. Understanding the clinical spectrum, mechanisms, and practical management of critical-illness-related hypercortisolism is essential for intensivists, endocrinologists, and other healthcare professionals involved in the care of critically ill patients.

Epidemiology / Disease Burden

The incidence of CIR-H varies across patient populations and is influenced by the underlying etiology of critical illness, such as sepsis, trauma, acute respiratory distress syndrome, and major surgery. Recent cohort studies report that up to 60-80% of patients in intensive care units (ICUs) display biochemical evidence of hypercortisolism during the acute phase of illness. The burden is particularly high in patients with multi-organ dysfunction, prolonged ICU stays, or those requiring vasopressor support. Notably, CIR-H has been associated with increased mortality, secondary infections, and prolonged recovery periods, underlining its clinical significance.

Pathophysiology

CIR-H arises from complex interactions between the hypothalamic-pituitary-adrenal (HPA) axis, inflammatory mediators, and peripheral tissue responses. During critical illness, pro-inflammatory cytokines such as interleukin-6 and tumor necrosis factor-alpha stimulate corticotropin-releasing hormone (CRH) and adrenocorticotropic hormone (ACTH) secretion, resulting in adrenal hypersecretion of cortisol. Concomitantly, there is reduced cortisol clearance due to impaired hepatic metabolism and decreased expression of cortisol-inactivating enzymes. Moreover, tissue resistance to cortisol may develop, driven by altered glucocorticoid receptor expression and signaling. This multifaceted pathophysiology reflects both compensatory mechanisms to counteract stress and potential maladaptive consequences when hypercortisolism is prolonged.

Risk Factors

Several risk factors predispose critically ill patients to hypercortisolism. These include severe systemic inflammation (e.g., sepsis, pancreatitis), major trauma, extensive burns, and major surgical procedures. Additional contributors are advanced age, pre-existing endocrine disorders (such as Cushing syndrome or adrenal adenomas), chronic steroid therapy, and genetic factors influencing HPA axis responsiveness. Patients with pre-morbid comorbidities, such as diabetes mellitus or chronic liver disease, may be particularly susceptible to dysregulated cortisol dynamics during critical illness.

Clinical Features

The clinical manifestations of CIR-H are often subtle and may be masked by the underlying critical illness. Typical features of chronic hypercortisolism, such as central obesity, striae, or facial rounding, are rarely seen acutely. Instead, CIR-H may present with hyperglycemia, fluid retention, hypertension, impaired wound healing, and increased susceptibility to infections. Myopathy, delirium, and psychiatric disturbances can also be exacerbated. Importantly, hypercortisolism may contribute to catabolic states, muscle wasting, and delayed convalescence in ICU survivors.

Diagnosis

Diagnosing CIR-H is challenging due to dynamic changes in cortisol secretion and binding during critical illness. Biochemical confirmation typically relies on measurement of total serum cortisol levels, with values exceeding 25-30 µg/dL (690-830 nmol/L) suggestive of hypercortisolism in the ICU context. However, alterations in cortisol-binding globulin (CBG) and albumin can confound interpretation. Free cortisol measurements (via equilibrium dialysis or mass spectrometry) may offer greater specificity, though these assays are not widely available. Short corticotropin stimulation tests are generally not recommended in the acute phase, as adrenal responsiveness is variably altered. Clinical suspicion should be heightened in patients with unexplained hyperglycemia, refractory shock, or secondary infections.

Treatment & Management

Management of CIR-H is primarily supportive and revolves around addressing the underlying precipitating illness. There is currently no consensus on pharmacological interventions to lower cortisol levels in the absence of overt Cushingoid features or life-threatening complications. Glucocorticoid antagonists (e.g., mifepristone) or synthesis inhibitors (e.g., ketoconazole, etomidate) have been explored in refractory cases, but robust evidence is limited. Glycemic control, infection surveillance, and early mobilization are crucial supportive measures. In cases where exogenous glucocorticoids are indicated (e.g., adrenal insufficiency, refractory septic shock), judicious dosing and frequent reassessment are essential to avoid exacerbating hypercortisolism.

Recent Advances / Emerging Therapies

Emerging research has focused on improved diagnostic modalities, such as direct free cortisol assays and novel biomarkers of tissue-specific cortisol action. Advances in understanding glucocorticoid receptor isoforms and tissue sensitivity may pave the way for targeted therapies. Pilot trials are evaluating selective glucocorticoid receptor modulators and inhibitors of cortisol synthesis in specific subgroups of critically ill patients with adverse hypercortisolemic profiles. Additionally, personalized medicine approaches integrating genetic, biochemical, and clinical data hold promise for stratifying risk and tailoring management strategies in the future.

Guideline Recommendations

Current guidelines from leading critical care and endocrinology societies emphasize the importance of recognizing CIR-H as an adaptive response in most critically ill patients. Routine cortisol-lowering therapy is not recommended unless there is evidence of glucocorticoid-induced complications or coexisting adrenal neoplasia. Measurement of serum cortisol should be reserved for patients with unexplained shock or clinical suspicion of adrenal dysfunction. For those requiring exogenous steroid replacement, stress-dose protocols should be individualized and titrated based on clinical response, with close monitoring for adverse effects.

Conclusion

Critical-illness-related hypercortisolism is a frequent and often underrecognized phenomenon with significant clinical implications in the ICU setting. While primarily adaptive, excessive or prolonged cortisol elevation can contribute to morbidity and impede recovery. Healthcare professionals should maintain a high index of suspicion, apply evidence-based diagnostic criteria, and prioritize supportive management tailored to individual patient needs. Ongoing research into the mechanisms and therapeutic modulation of CIR-H may offer new avenues for improving outcomes in the critically ill population.